• This test expands Roche's early diagnostics portfolio by screening for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), and Sickle Cell Disease (SCD) simultaneously.
  • Catching these conditions shortly after birth empowers clinicians to choose life-changing treatments sooner, before irreversible symptoms or permanent damage manifest.
  • The IVDR-approved test provides private and academic hospital laboratories with a ready-to-use solution that easily integrates into existing workflows.